Cytochrome P450-Mediated Drug Interactions - 19/06/18
Doi : 10.1016/S1056-4993(18)30135-4
David A. Flockhart, MD., PhD a, ⁎, Jessica R. Oesterheld, MD b
a From the Departments of Medicine and Pharmacology and the Pharmacogenetics Core Laboratory, Division of Clinical Pharmacology, Georgetown University Medical Center, Washington, DC
b The Department of Psychiatry, Division of Child Psychiatry, University of South Dakota School of Medicine, Sioux Falls, South Dakota
*Address reprint requests to: Jessica R. Oesterheld, MD 2812 South Louise Avenue, Sioux Falls, SD 571052812 South Louise AvenueSioux FallsSD57105
Résumé |
This article reviews hepatic P450-drug-metabolizing cytochromes (CYPs). Starting with the nomenclature and development of CYPs, the authors discuss concepts necessary to understand clinically relevant CYP-based drug interactions. Polymorphisms, substrates, inhibitors, and inducers of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2El, and the CYP3A subfamily are reviewed. Case histories, CYP lists, and CYP websites are provided to highlight drug interactions relevant to child psychiatrists.
Le texte complet de cet article est disponible en PDF.| This work was supported in part by grants R01-GM56898-01 and T32-9M08386 from the National Institute of General Medical Sciences, Bethesda, MD |
© 2000
Elsevier Inc. Tous droits réservés.
Vol 9 - N° 1
P. 43-76 - janvier 2000 Retour au numéro
Article précédent
- Pharmacogenetics: Promise and Potential in Child and Adolescent Psychiatry
- George M. Anderson, Edwin H. Cook
- Pharmacotherapy of Attention Deficit Hyperactivity Disorder
- Thomas Spencer, Joseph Biederman, Timothy Wilens
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?